Gareth Jones

Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…

BACKGROUND: Several lines of evidence show mitochondrial damage and bioenergetic failure in ulcerative colitis (UC). However, little is known about the specific pathogenic metabolic processes that influence epithelial function and repair in UC1…